AMCP comment letter on state legislation on interchangeable biologic products.
AMCP comment letter on state legislation on pharmacist substitution of biologics.
AMCP comments on state legislation on substitution of biologics.
AMCP comments on state legislation on interchangeable biologics.
AMCP comment letter on state legislation on interchangeable biologic products.
AMCP comments on state legislation on substitution of interchangeable biologics.
AMCP CEO Blog: It was only ten years ago when biosimilars were so new that the New York Times described them as “so-called.” As late as five years ago newspapers put quotation marks around the term, as in “biosimilars.”
